Interstitial radiotherapy and prostate cancer. Review of the literature;Radiothérapie interstitielle et cancer prostatique Analyse de la littérature

Progres en Urologie

Volumn 9, Issue 3, 1999, Pages 440-451

  Peneau, Michel ^a  

^a CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

Author keywords

Biopsies; Interstitial radiotherapy; Morbidity; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD; BRACHYTHERAPY; CANCER STAGING; COMPARATIVE STUDY; FRANCE; HUMAN; MALE; MEDICAL SOCIETY; MEDLINE; MONITORING; PATHOLOGY; PROSTATE TUMOR; REVIEW;

BRACHYTHERAPY; FRANCE; HUMANS; MALE; MEDLINE; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL;

EID: 0041629339     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. American Society For Therapeutic Radiology and Oncology Consensus Panel : Consensus statement : guidelines for PSA following radiation therapy. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37 : 1035-1041.
2. AMIN P.P., VINES E.F., AMPEY L.L. : The significance of prostate biopsy following bachy therapy for prostate cancer. J. Urol., 1997, 157 (suppl.), 143 A.
3. ARTERBERY V.E., WALLNER K., ROY J., FUKS Z. : Short term morbidity from CT-planed transperineal I-125 prostate implants. Int. J. Radiat. Oncol. Biol. Phys., 1993, 25 : 661-667.
4. BETERMANN H., HANSEN J., BRIX F., QUIRIN A. : Ultrasonically guided interstitial high dose rate brachytherapy with an iridium - 192 technique : preliminary results in locally confined prostate cancer, in : Brachytherapy HDR and LDR, MARTINEZ AA, ORTON CG and MOULD RF (Eds), Chapter 24, Nucletron : Columbia, 1990.
5. BEYER D.C., PRIESTLEY J.P. : Biochemical disease-free survival following I-125 prostate implantation. Int. J. Radiat. Oncol. Biol. Phys., 1997, 32 : 559-563.
6. BLASKO J.C., GRIMM P.D., RAGDE H. : External beam irradiation with palladium 103 implantation for prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 1994, 30 (S1) : 219.
7. BLASKO J.C., RAGDE H. : Transperineal ultrasound guided Palladium 103 brachytherapy for prostate carcinoma. J. Urol., 1995, 153 (suppl.) : (P.) 385a.
8. BLASKO J.C., RAGDE H., GRIMM P.D. : Transperineal ultrasound guided implantation of the prostate morbidity and complications. Scand. J. Urol. Nephrol. Suppl, 1991, 137 ; 113-118.
9. BLASKO J.C., RAGDE H., LUSE R.W., CAVANAGH W., GRIMM P.D. : Should brachytherapy be considered a therapeutic option in localized prostate cancer ? Urol. Clin. North Am., 1996, 23 : 633-650.
10. BLASKO JC, RAGDE H, SCHUMACHER D : transperineal percutaneous iodine 125 implantation for prostate cancer using transrectal ultrasound and template guidance. Endocurietherapy Hyperthermia Oncology, 1987, 3 : 131-139.
11. BLASKO J.C., WALLNER K., GRIMM P.D., RAGDE H. : Prostate specific antigen based disease control following ultrasound guided 125 iodine implantation for stage T1/ T2 prostate carcinoma? J. Urol., 1995, 154 : 1096-1099.
12. CARLTON C.E., SCARDINO P.T. : Long term results after combined radio seed implantation and external beam radiotherapy for localized prostatic cancer. In : Brachytherapy of Prostatic Cancer, Federal Republic of Germany, Bruggmoser G., Mould R.F. (Eds.), 1991, 53-66.
13. CATALONA W.J., SMITH D.S. : Cancer control after Antomical radical retropubic prostatectomy ; an update. J. Urol., 1998, 159 (suppl.) : (P.) 253A.
14. CRITZ F.A., LEVINSON A.K., WILLIAMS W.H. : A precise definition of disease free survival following irradiation for prostate cancer. J. Urol., 1997, 157 (suppl.) : (P) 291 A.
15. CRITZ F.A., LEVINSON A.K., WILLIAMS W.H., HOLLADAY D.A. : Prostate specific antigen Nadir : the optimum level after irradiation for prostate cancer. J. Clin. Oncol., 1996, 14 : 2893-2900.
16. CRITZ F.A., LEVINSON A.K., WILLIAMS W.H., HOLLADAY D.A., HOLLADAY C.T., GRIFFIN V.D. : The PSA nadir goal fo radiotherapy of prostate cancer is £0,2ng/ml. J. Urol., 1998, 159 (suppl.) : (P.) 218a.
17. CRITZ F.A., TARLTON R.S., HOLLADAY D.A. : Prostate specific antigen monitored combination radiotherapy for patients with proslate cancer, 1-125 implants followed by external beam radiation. Cancer, 1995, 75 : 2383-2391.
18. CROOK J.M., BAHADUR Y.A., BOCIEK R.G., PERRY G.A., ROBERTSON S.J., ESCHE B.A. : Radiotherapy for Localized Prostate Carcinoma : The Correlation of Pretreatment Prostate Specific Antigen and Nadir Prostate Specific Antigen with Outcome as Assessed by Systematic Biopsy and Serum Prostate Specific Antigen. Cancer. 1997, 79 : 328-336.
19. CROOK J.M., BAHADUR Y.A., ROBERTSON S.J., PERRY G.A., ESCHE B.A. : Evaluation of Radiation Effect, Tumor Differentiation, and Prostate Specific Antigen Staining in Sequential Prostate Biopsies after External Beam Radiotherapy for Patients with Prostate Carcinoma. Cancer, 1997, 79 : 81-89.
20. CROOK J.M., ROBERTSON S.J., COLLIN G., ZALESKI V., ESCHE B.A. : Clinical relevance of lransrectal ultrasound biopsy and serum prostate specific antigen following external beam radiotherapy for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 1993, 27 : 31-37.
21. DATTOLI M.J., WASSERMAN S.G., KOVAL J.M., SORACE R.A., CASH J., WALNER K.E. : Conformal brachytherapy boost to external beam irradiation for localized high risk prostate cancer (Abstract). Int. J. Radiat. Oncol. Biol. Phys., 1995, 32 (S1) : 251.
22. DAVIS J.W., HOLM P., WRIGHT G.L., KUBAN D., EL-MAHDI A., SCHELLHAMMER P.F. : The durable effect of external beam radiation therapy for prostate cancer can it be identified ? J. Urol. 1998, 159 (suppl.) : (P.) 64 A
23. EPSTEIN J.I., PARTIN A.W., SAUVAGEOT J. : Prediction of progression following radical prostatectomy : multivariate analysis of 721 men with long-term follow up. Am. J. Surg. Pathol., 1996, 20 : 286-292.
24. FREIHA F.S., BAGSHAW M.A. : Carcinoma of the prostate : results of post-irradiation biopsy. Prostate, 1984, 5 : 19-25.
25. HAIE-MEDER C., COURT B., PERRIN J.L., WIBAULT E., LARTIGAU E., GERBAULET A. : Curiethérapie dans les adénocarcinomes prostatiques. Ann. Urol. (Paris), 1994, 28 : 295-301.
26. HILARIS B.S., FUKS Z., NORI D., FAIR W.A., WHITMORE W.F.: Interstitial irradiation in prostatic cancer : report of 10 year results, in : Interventional Radiotherapy Techniques - Brachytherapy, Berlin, Springer, 1989.
27. HOLM H.H., JUUL N., PEDERSEN J.F., HANSEN H., STROYER I. : Transperineal 125 Iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J. Urol., 1983, 130 : 283-286.
28. KABALIN J.N., HODGE K.K., MCNEAL J.E., FREIHA F.S., STAMEY T.A. : Identification of residual cancer in the prostate following radiation therapy. Role of transrectal ultrasound guided biopsy and prostate specific antigen. J urol, 1989, 142 : 326-331.
29. KAVADI V.S., ZAGARS G.K., POLLACK A. : Serum Prostate Specific Antigen after radiation therapy for clinically localized prostate cancer : pronostic implications. Int. J. Radiat. Oncol. Biol. Phys., 1994, 30 : 279-287
30. KAYE K.W., OLSON D.J., PAYNE J.T. : Detailed preliminary analysis of 125 iodine implantation for localized prostate cancer using percutaneous approach. J. Urol., 1995, 153 : 1020-1025.
31. KHAN K., THOMPSON W., BUSH S., STIDLEY C. : Transperineal percutaneous iridium 192 interstitial template implant of the prostate : results and complications in 321 patients. Int. J. Radiat. Oncol. Biol. Phys., 1992, 22 : 935-939.
32. KLEINBERG L., WALLNER K., ROY J., ZELEFSKY M., ARTERBERY V.E., FUKS Z., HARRISON L. : Treatment related symptoms during the first year following transperineal I-125 prostate implantation. Int. J. Radiat. Oncol. Biol. Phys., 1994, 28 : 985-990.
33. KOPROWSKI C.D., BERRENSTOCK K.G., BOROFSKI A.M., ZIEGLER J.C., LIGHTFOOT D.A., BRADY L.W. : External beam radiation versus 125 iodine implants in the definitive treatment of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 1991, 21 : 955-960.
34. KUBAN D.A., EL MAHDI A.M., SCHELLHAMMER P. : The significance of post irradiation prostate biopsy with long-term follow up. Int. J. Radiat. Biol. Phys., 1992, 24 : 409-414.
35. KUBAN D.A., EL MAHDI A.M., SCHELLHAMMER P.F. Iodine 125 interstitial implantation for prostate cancer : what have we learned 10 years later? Cancer, 1989, 63 : 2415-2420.
36. KUBAN D.A., EL MAHDI A.M., SCHELLHAMMER P.F. Prostate specific antigen for pretreatment prediction and post treatment evaluation of outcome after definitive irradiation for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1995, 32 : 307-316.
37. KURTH K.H., ALTWEIN J.E., SKOLUDA D., HOHENFELLNER R. : Follow up of irradiated prostatic carcinoma by aspiration biopsy. J. Urol., 1977, 117 : 615-617.
38. LANNON S.G., EL-ARABY A.A., JOSEPH P.K. : Long term results of combined interstitial gold seed implantation by external beam irradiation in localized carcinoma of the prostate. Br. J. Urol., 1993, 72 : 782-791.
39. LEVINSON A.K., CRITZ F.A., WILAMS W.H., HOLLADAY D.A., HOLLADAY C.T., GRIFFIN V.D. : Prostate cancer Treated by Simultaneous Radiotherapy : I-125 prostate implant followed by external-Beam Radiation. J. Urol., 1998, 159 (suppl.) : (P.) 63A.
40. MARTINEZ A. : Experience with LDR and HDR brachytherapy for locally advanced prostate cancer. Personnal communication, Prostate Cancer, the role of interstitial implantation. Fourth Annual Symposium; Seattle, USA, 1993.
41. MORTON J.D., PESCHEL R.E. : Iodine-125 implants versus external beam radiotherapy for stages A2, B and C prostate cancer : Int. J. Radiat. Oncol. Biol. Phys., 1988, 14 : 1153-1157.
42. NAG S., SCARPEROTH D.D., BADALAMEND R., HALL S.A., BURGERS J. : Transperineal palladium 103 prostate brachytherapy : analysis of morbidity and seed migration : Urology, 1995, 45 : 87-92.
43. PIERQUIN B., WILSON J.F., CHASSAGNE D. : Radionucleides and sources used in brachytherapy. Prostate, Modern Brachytherapy. Paris, France, Masson, 1987, 7-15.
44. POLASCIK T.J., POUND C.R., DE WEESE T.L., WALSH P.C. : Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for clinically localized prostate cancer : a 7 year biochemical (PSA) progression analysis. Urology, 1998, 51 : 884-889
45. PRESTIDGE B.R., HOAK D.C., GRIMM P.D., RAGDE H., CAVANAGH W., BLASKO J.C. : Post-treatment biopsy results following interstitial brachytherapy in early stage prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37 : 31-39.
46. PRESTIDGE B.R., KAPLAN I., COX R.S., BAGSHAW M.A. : The clinical significance of a positive postirradiation prostatic biopsy without metastases. Int J. Radiat. Oncol. Biol. Phys., 1992, 24 : 403-408.
47. RAGDE H., BLASKO J.C., GRIMM P.D., KENNY G.M., SYLVESTER J.E., HOAK D.C., LANDIN K., CAVANAGH W. : Interstitial Iodine - 125 Radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer, 1997, 80 : 442-453.
48. RAGDE H., BLASKO J.C., GRIMM P.D., KENNY G.M., SYLVESTER J.E., LANDIN K. : 5 years observed biomechemical disease for survival in T1-T2 prostate cancer patients treated with brachytherapy. J. Urol., 1998, 159 (suppl.) : (P.) 63a.
49. SCARDINO P.T. : The pronostic significance of biopsies after radiotherapy for prostatic cancer. Seminars in Urology, 1983, 1 :243-252.
50. STOCK R.G., STONE N.N. : Patient selection for transperineal radioacfive seed implantation in the treatment of prostate cancer. J. Urol., 1997, 157 (suppl.) : (P) 293 A
51. STOCK R.G., STONE N.N., DEWYNGAERT J.K., LAVAGNINI P., UNGER P.D. : Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer, 1996, 77 : 2386-2392.
52. STOCK R.G., STONE N.N., IANNUZZI C. : Sexual potency following interactive ultrasound guided brachytherapy for prostate cancer. Inter. J. Radiat. Oncol. Biol. Phys., 1996, 35 : 267-272.
53. STONE N.N., RAMIN S.A., WESSON M.F., STOCK R., UNGER P.D., KLEIN G. : Laparoscopic pelvic lymph mode dissection combined with real time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J. Urol., 1995, 153 : 1555-1560.
54. STONE N.N., STOCK R.G., UNGER P. Prostate biopsy results following brachytherapie for localized prostate cancer : an analysis of variables influencing outcomes. J. Urol., 1997, 157 (suppl.) : (P) 418 A.
55. STROMBERG J., MARTINEZ A., GONZALEZ J., EDMUNDSON G., OHANIAN N., VICINI F., HOLLANDER J., GUSTAFSON G., SPENCER W., YAN D.I., BRABBINS D. : Ultrasound guided higth dose rate conformal brachytherapy boast in prostate cancer : treatment description and preliminary results of a phase I/II clinical trial. Int. J. Radiat. Oncol. Biol. Phys., 1995, 33 : 161-171.
56. SYED A.M., PUTHAWALA A., AUSTIN P., CHERLOW J., PERLEY J., TANSEY L., SHANBERG A., SAWYER D., BAGHDASSARIAN R., WACHS B., TOMASULO J., RAO J., SYED R. : Temporary iridium 192 implants in the management of carcinoma of the prostate. Cancer, 1992, 69: 2515-2524.
57. WALLNER K., ROY J., HARRISON L. : Tumor control and morbidity following transperineal iodine 125 implantation for stage T1-T2 prostatic carcinoma. J. Clin. Oncol., 1996, 14 : 449-453.
58. WALLNER K., ROY J., ZELEFSKY, FUKS Z., HARRISON L. : Short term freedom disease progression after I-125 prostate implantation. Int. J. Radiat. Oncol. Biol. Phys , 1994, 30 : 405-409.
59. WEYRICH T.P., KANDZARI S.J., JAIN P.P. : Iodine 125 seed implants for prostatic carcinoma : five and ten years follow up. Urology, 1993, 41 : 122-126.
60. WHITMORE W.F., HILARIS B., GRABSTALD H. Retropubic implantation of iodine 125 in the treatment of prostatic carcinoma. J. Urol., 1972, 108 : 918-920.
61. WIRTH B., LOCH T., BRÜSKE T., KOVACS G., KIMMING B., BERTERMANNN H., STÖCKLE M. : Transrectal ultrasound (TRUS) guided combined high dose rate (H.D.R) brachytherapy of localized prostate cancer : 10 years of experience with a minimum follow up of 5 years. J. Urol., 1997, 157 (suppl.) : (P.) 289 A.
62. ZAGARS G. K., POLLACK A., KAVADI V.S., VON ESCHENBACH A.C. : Prostate Specific Antigen and radiation therapy for clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1995, 32 : 293-306.
63. ZAGARS G.K. : Prostate specific antigen as an outcome variable for T1 and T2 prostatic cancer treated by radiation therapy. J. Urol., 1994, 152 : 1786-1791.
64. ZAGARS G.K., POLLACK A., KAVADI V.S., Von ESCHENBACH A.C. : Prostate specific antigen and radiation therapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1995, 32 : 293-306.
65. ZELEFSKY M.J., LEIBEL S.A., WALLNER K.E., WHITMORE W.F. Jr., FUKS Z. : Significance of normal serum prostate specific antigen in the follow up period after definitive radiation therapy prostatic cancer. J. Clin. Oncol., 1995, 13 : 459-463.
66. ZIETMAN A.L., COEN J.J., SHIPLEY W.U., WILLET C.G., EFIRD J.T. Radical radiation therapy in the management of prostatic adenocarcinoma the initial prostate specific antigen value as a predictor of treatment outcome. J. Urol., 1994, 151 : 640-645.